|

Osimertinib Clinical Trials

44 actively recruiting trials across 17 locations

No change since May 2026

Also known as: AZD 9291, AZD-9291, AZD9291, AZD9291, Tagrisso, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc. +6 more

Pipeline

Phase 1: 10Phase 2: 16Phase 3: 9Phase 1/2: 6

Top Sponsors

AstraZeneca4
Memorial Sloan Kettering Cancer Center3
TYK Medicines, Inc2
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2
National Cancer Institute (NCI)2

Indications

Cancer44
Lung Cancer42
Non Small Cell Lung Cancer14
Stage IV Lung Cancer AJCC v85
NSCLC5

Other20 trials

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase 3

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Phase 1

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Phase 3

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

Phase 2

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Phase 2

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Phase 3

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

N/A

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

Phase 2

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

Phase 2

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Phase 2

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

Phase 2

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Phase 1

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Phase 2

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Phase 3

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Phase 1/2

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Phase 2

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Phase 2

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Phase 2

Birmingham, Alabama3 trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1/2

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

University of Alabama at Birmingham

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Anchorage, Alaska2 trials

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Anchorage Associates in Radiation Medicine

Phase 3

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Anchorage Associates in Radiation Medicine

Phase 2

Duarte, California2 trials

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

City of Hope Medical Center

Phase 2

First in Human Study of AZD9592 in Solid Tumors

Research Site

Phase 1

Los Angeles, California2 trials

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Valkyrie Clinical Trials

Phase 1/2

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Sacramento, California2 trials

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

University of California, Davis Comprehensive Cancer Center

Phase 1/2

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

UC Davis Cancer Center (Data Collection Only)

Phase 2

San Francisco, California2 trials

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

University of California, San Francisco

Phase 1

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1/2

Daphne, Alabama1 trial

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2

Fayetteville, Arkansas1 trial

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site

Phase 3

Beverly Hills, California1 trial

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Cedars-Sinai Cancer at Beverly Hills (THO)

Phase 1

Fountain Valley, California1 trial

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Site

Phase 3

Denver, Colorado1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Sarah Cannon Research Institute at HealthONE

Phase 1

Miami, Florida1 trial

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

BAPTIST ALLIANCE - MCI (Data Collection Only)

Phase 2

Atlanta, Georgia1 trial

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Emory University Hospital/Winship Cancer Institute

Phase 1

Lexington, Kentucky1 trial

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center

Phase 1

Boston, Massachusetts1 trial

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Massachusetts General Hospital

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 1/2

Columbus, Ohio1 trial

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.